Salmonella vaccine reaches final stage for USDA approval

May 16, 2012, Tallahassee, FL – Global Green, Inc. has announced that the Company has received the final report on the model Efficacy Study conducted on the Company’s patented vaccine, Salmogenics, to be used to protect poultry from Salmonella bacteria. This study, conducted by AHPharma, an independent food safety and animal health research firm, is an important step towards receiving USDA approval for Salmogenics.

The Study was performed using 3,036 chickens, specifically broilers. Those chickens injected in ovo (in the egg before the chick is hatched) with Salmogenics showed a significant reduction in Salmonella bacteria.

The study reports that the “Salmogenics Vaccine appears to provide enough protection against all strains of Salmonella tested.” Clearly, Salmogenics provided protection in broilers against the spread of Salmonella. The conclusion of the study reports that reducing Salmonella in chickens prior to them being processed and sold to the public is critical in reducing Salmonella levels.

“Our patented Salmogenics Vaccine is in the fourth and final phase required for USDA approval. The final report on the data in the Study conducted by AHPharma is very encouraging and will be forwarded to the USDA,” commented Dr. Mehran Ghazvini, Chairman and CEO, Global Green, Inc.

Salmogenics Utilizes Unique Application

When Salmonella is discovered in the flock during the processing stage, the costs to eradicate the disease are staggering. Salmogenics is unique in that it is injected directly into the egg, before the chick is hatched, improving the immune system, health and welfare of the chicken. The vaccine reduces levels of Salmonella in the flock and reduces the risk of Salmonella contamination in the processing plant.

Leading Poultry Industry Expert Confirms Significance of Vaccine

The historic approach for Salmonella control ignores chicken live growing practices and attempts to completely eliminate Salmonella and other foodborne bacteria during final processing. A Salmonella vaccine addressing vigorous strains that are hard to destroy is important,” commented James McNaughton, PhD, leading independent poultry research expert.

Global Green, Inc. plans to manufacture, market and sell the patented, exclusive, licensed vaccine known as the “Salmogenics Vaccine.” Salmogenics was developed by Nutritional Health Institute Laboratories, LLC (a research affiliate and majority shareholder) to combat Salmonella bacteria in eggs and poultry. The vaccine is currently in the final stage of the USDA approval process. The Company has received approval from FINRA to begin trading publicly on the OTC market and has applied for DTC approval.

For more information, visit www.globalgreeninc.org.